Advertisement
Markets

Novartis: In the Pipeline

This major pharmaceutical company may be the best positioned among its peers.

Novartis AG, the giant, Swiss-based drugmaker, sells at about $57 a share -- just $5 more than it sold for in 1999. But the stock's tepid appreciation seems likely to accelerate over the next several years.

Novartis on Monday reported that first-quarter earnings rose 32% from the same period a year ago, to 83 cents per share. Part of the increase was attributed to lower marketing costs, but most was because of a 13% increase in sales, to $8.3 billion. The stock, however, barely budged because analysts -- while surprised by the robust earnings number -- had, on average, expected revenues of $8.5 billion.

Advertisement - Article continues below

But Novartis may well be the best positioned of the major pharmaceutical companies. It has four blockbuster drugs -- drugs with annual sales over $1 billion. They are leukemia drug Gleevec; Lotrel and Diovan for hypertension; and Zometa, another cancer drug. Sales of all four are still growing at double-digit annual rates.

The pipeline? "That's where it gets really exciting," says Trevor Polischuk, an analyst with Orbimed Advisors, which manages Eaton Vance Worldwide Health Sciences fund. Novartis is the largest holding in the fund at more than 7% of assets. Novartis just filed with the Food and Drug Administration for approval of two new drugs, one for hypertension and one for diabetes. "They'll be first-in-class drugs," says Polischuk. "They're not 'me-too' drugs." In addition, he says, Novartis boasts "a whole host" of other promising drugs in its pipeline.

Advertisement
Advertisement - Article continues below

What's more, Novartis faces few expiring patents in the near future, a problem that bedevils many other big pharmaceutical companies. Only one of its key drugs will lose patent protection by the end of the decade. Novartis must contend with some of the same pressures that other drug companies face, however -- most important, pressure by governments around the world to stem rapidly rising drug costs.

Chief executive Dan Vasella has done a fine job fostering the right atmosphere to keep research scientists developing new drugs. He worries some on Wall Street, though, because he's acquisitive. But Novartis's most recent purchase, biotech company Chiron, looks promising. "Novartis has deep pockets, tons of cash flow and a great balance sheet," Polischuk says. Indeed, debt is just 4% of capital, and the firm has $11 billion in cash and securities.

The stock (symbol NVS) sells at 17 times Polischuk's 2006 earnings estimate of $3.32 per share. That's about the same price-earnings ratio as most of Novartis's rivals. But Polischuk figures that Novartis's earnings will grow 17% per year through 2009 -- much more than its competitors. "On a price-earnings-to-growth basis, Novartis is the cheapest of all the big pharma companies" he says.

--Steven Goldberg

Advertisement

Most Popular

12 Tax Deadlines for July 15 (It's Not Just the Due Date for Your Tax Return)
tax deadline

12 Tax Deadlines for July 15 (It's Not Just the Due Date for Your Tax Return)

Between due dates for paying estimated taxes, IRA or HSA contributions, and other deadlines, there's more to do by July 15 than just filing your feder…
July 14, 2020
What Time is the Tax Deadline Today?
tax deadline

What Time is the Tax Deadline Today?

If you're waiting until the last possible minute to file your tax return, at least know how much time you have.
July 15, 2020
65 Best Dividend Stocks You Can Count On
stocks

65 Best Dividend Stocks You Can Count On

These 65 Dividend Aristocrats are an elite group of dividend stocks that have reliably increased their annual payouts every year for at least a quarte…
July 8, 2020

Recommended

The Pros' Top 5 Industrial Stocks
investing

The Pros' Top 5 Industrial Stocks

The industrial sector is lagging badly this year, but anytime there's carnage, there is also opportunity, analysts say.
July 16, 2020
Closing Bell 7/15/20: Moderna's Vaccine Progress Pumps Up the Market
Markets

Closing Bell 7/15/20: Moderna's Vaccine Progress Pumps Up the Market

Encouraging news from human trials of Moderna's (MRNA) COVID-19 vaccine triggered market gains Wednesday, including a massive run in small caps.
July 15, 2020
Closing Bell 7/14/20: Momentum Swings the Dow's Way
Markets

Closing Bell 7/14/20: Momentum Swings the Dow's Way

Many of the Dow Jones' economically sensitive components pushed higher on Tuesday on the back of slightly better COVID-19 data from a few U.S. hotspot…
July 15, 2020
Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs
Markets

Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs

A rapid rally to start the week, sparked by encouraging vaccine news from Pfizer and BioNTech, collapsed in the afternoon.
July 13, 2020